Spring Bank Pharmaceuticals, Inc. Employee Directory

BiotechnologyMassachusetts, United States11-50 Employees

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics through its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. This approach yields short segments of nucleic acids designed to selectively influence the activity of proteins implicated in various diseases, with the most advanced candidate, SB 11285, targeting the STING pathway for cancer treatment. The company is pursuing a broader STING portfolio, including antagonists for inflammatory diseases and an antibody-drug conjugate program for oncology applications, reflecting a broader strategy around modulating innate immune responses.

Based in Hopkinton, Massachusetts, the firm operates within the biotechnology research sector, collaborating with established institutions and pursuing opportunities in cancer and inflammatory diseases. As a clinical-stage entity with a relatively small team, it emphasizes advancing its SMNH-based therapies from discovery toward clinical development. The company’s activities situate it at the intersection of nucleic acid therapeutics and immuno-oncology, aiming to address unmet needs through targeted modulation of the STING pathway.

Sign up for free to view info

Company overview Email format